{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lipid+Metabolism%2C+Inborn+Errors&page=2",
    "query": {
      "condition": "Lipid Metabolism, Inborn Errors",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lipid+Metabolism%2C+Inborn+Errors&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T13:43:41.991Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00827606",
      "title": "Atorvastatin Three Year Pediatric Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "atorvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "6 Years to 15 Years"
      },
      "enrollment_count": 272,
      "start_date": "2009-03",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-06-10T13:43:41.991Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Washington D.C., District of Columbia • Gainesville, Florida + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00827606"
    },
    {
      "nct_id": "NCT05174039",
      "title": "An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Batten Disease"
      ],
      "interventions": [
        {
          "name": "Miglustat 100 milligrams (mg) Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beyond Batten Disease Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2022-03-10",
      "completion_date": "2024-05-30",
      "has_results": true,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-06-10T13:43:41.991Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05174039"
    },
    {
      "nct_id": "NCT06663358",
      "title": "A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "Pegunigalsidase-alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chiesi Farmaceutici S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2024-11-06",
      "completion_date": "2029-11",
      "has_results": false,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-06-10T13:43:41.991Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06663358"
    },
    {
      "nct_id": "NCT04470713",
      "title": "Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "GM1 Gangliosidosis",
        "GM2 Gangliosidosis",
        "Gaucher Disease, Type 2",
        "Tay-Sachs Disease",
        "AB Variant Gangliosidosis GM2",
        "Sandhoff Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Idorsia Pharmaceuticals Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Months and older"
      },
      "enrollment_count": 226,
      "start_date": "2019-07-31",
      "completion_date": "2021-10-30",
      "has_results": false,
      "last_update_posted_date": "2021-11-08",
      "last_synced_at": "2026-06-10T13:43:41.991Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Rochester, Minnesota • Fairfax, Virginia",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04470713"
    },
    {
      "nct_id": "NCT06488261",
      "title": "Long Term Follow-Up for Safety of AVR-RD-02",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gaucher Disease"
      ],
      "interventions": [
        {
          "name": "AVR-RD-02",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "John Bernat",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2024-02-21",
      "completion_date": "2037-10",
      "has_results": false,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-06-10T13:43:41.991Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06488261"
    },
    {
      "nct_id": "NCT01358188",
      "title": "Exploration of Immunity in Gaucher Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gaucher Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "O & O Alpan LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2011-04",
      "completion_date": "2016-05-02",
      "has_results": false,
      "last_update_posted_date": "2017-04-04",
      "last_synced_at": "2026-06-10T13:43:41.991Z",
      "location_count": 1,
      "location_summary": "Fairfax, Virginia",
      "locations": [
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01358188"
    },
    {
      "nct_id": "NCT01488097",
      "title": "Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cholesterol Ester Storage Disease (CESD)",
        "Lysosomal Acid Lipase Deficiency",
        "LAL-Deficiency"
      ],
      "interventions": [
        {
          "name": "sebelipase alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2011-12-12",
      "completion_date": "2017-06-21",
      "has_results": true,
      "last_update_posted_date": "2018-07-20",
      "last_synced_at": "2026-06-10T13:43:41.991Z",
      "location_count": 5,
      "location_summary": "Eureka, California • Sacramento, California • San Francisco, California + 2 more",
      "locations": [
        {
          "city": "Eureka",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01488097"
    },
    {
      "nct_id": "NCT04310163",
      "title": "Interviews and Video Capture in Patients With GM1 Gangliosidosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "GM1 Gangliosidosis"
      ],
      "interventions": [
        {
          "name": "Natural history",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "LYSOGENE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 25,
      "start_date": "2020-04-20",
      "completion_date": "2023-05-05",
      "has_results": false,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-06-10T13:43:41.991Z",
      "location_count": 1,
      "location_summary": "Plymouth, Massachusetts",
      "locations": [
        {
          "city": "Plymouth",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04310163"
    },
    {
      "nct_id": "NCT06056908",
      "title": "Shwachman Diamond Syndrome Registry and Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Shwachman-Diamond Syndrome",
        "Shwachman-Diamond Syndrome-Like"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 5000,
      "start_date": "2016-01-19",
      "completion_date": "2090-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-06-10T13:43:41.991Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Boston, Massachusetts • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06056908"
    },
    {
      "nct_id": "NCT03952637",
      "title": "A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lysosomal Diseases",
        "Gangliosidosis",
        "GM1"
      ],
      "interventions": [
        {
          "name": "AAV9-GLB1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Abdominal ultrasound",
          "type": "PROCEDURE"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Audiology assessment with ABR",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Bone density scan (DEXA)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Electrocardiogram (EKG)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Echocardiogram",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Electroencephalogram (EEG) awake and extended overnight",
          "type": "OTHER"
        },
        {
          "name": "Laboratory tests",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Lumbar puncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Brain MRI/MRS/fMRI",
          "type": "PROCEDURE"
        },
        {
          "name": "Neurocognitive testing",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Neurology exam",
          "type": "OTHER"
        },
        {
          "name": "PICC or other Central line placement",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Skeletal survey",
          "type": "PROCEDURE"
        },
        {
          "name": "Skin biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Speech and modified barium swallow study",
          "type": "PROCEDURE"
        },
        {
          "name": "Ophthalmology exam",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG",
        "DIAGNOSTIC_TEST",
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Months to 12 Years"
      },
      "enrollment_count": 54,
      "start_date": "2019-08-19",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-06-10T13:43:41.991Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03952637"
    }
  ]
}